Moderna (MRNA) Stock Overview
A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MRNA from our risk checks.
MRNA Community Fair Values
Create NarrativeSee what 236 others think this stock is worth. Follow their fair value or set your own to get alerts.
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.33 |
| 52 Week High | US$56.70 |
| 52 Week Low | US$23.15 |
| Beta | 1.11 |
| 1 Month Change | -11.01% |
| 3 Month Change | -6.85% |
| 1 Year Change | -51.61% |
| 3 Year Change | -85.57% |
| 5 Year Change | -72.29% |
| Change since IPO | 30.81% |
Recent News & Updates
Recent updates
Moderna: Q3 Earnings Preview - I Fear A Halloween Horror Show (Downgrade)
Oct 14Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Jul 18
MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK
Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing andMore Downside For Moderna Before The Breakthrough
Apr 22Moderna, Inc.'s (NASDAQ:MRNA) 27% Dip In Price Shows Sentiment Is Matching Revenues
Apr 04FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade)
Mar 31Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out
Mar 06Moderna, Inc.: Working Hard But Competition Is Working Harder
Feb 14
Vaccine Expansion Plans Could Shape Future Despite Market Challenges And Legal Risks
Strategic product innovation in combining vaccines could enhance long-term revenue streams and international market positioning.Moderna, Inc.'s (NASDAQ:MRNA) Business And Shares Still Trailing The Industry
Feb 03Moderna: The Good News Isn't Enough
Feb 03Moderna: Can They Benefit From Bird Flu? (Rating Upgrade)
Jan 10Moderna: 2025 Contrarian Play
Dec 31Moderna: Cutting Costs Might Not Be Enough
Dec 18Here's Why We're Watching Moderna's (NASDAQ:MRNA) Cash Burn Situation
Nov 30Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store
Nov 22Moderna: Assessing The Impact Of GSK's Patent Lawsuit
Oct 22Moderna: Still Bullish View
Sep 20Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling
Sep 12Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)
Aug 26Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic
Jul 30Moderna: Really Strong Competition
Jun 30Moment Of Truth Approaches For Moderna's RSV Vaccine
Jun 18Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor
May 23Moderna Q1: A Promising Pipeline Is Undervalued
May 15Shareholder Returns
| MRNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.5% | 0.8% | -1.7% |
| 1Y | -51.6% | 0.3% | 12.3% |
Return vs Industry: MRNA underperformed the US Biotechs industry which returned 0.3% over the past year.
Return vs Market: MRNA underperformed the US Market which returned 12.3% over the past year.
Price Volatility
| MRNA volatility | |
|---|---|
| MRNA Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRNA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MRNA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5,800 | Stéphane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis.
Moderna, Inc. Fundamentals Summary
| MRNA fundamental statistics | |
|---|---|
| Market cap | US$9.20b |
| Earnings (TTM) | -US$2.90b |
| Revenue (TTM) | US$3.08b |
Is MRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRNA income statement (TTM) | |
|---|---|
| Revenue | US$3.08b |
| Cost of Revenue | US$5.28b |
| Gross Profit | -US$2.20b |
| Other Expenses | US$704.00m |
| Earnings | -US$2.90b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.43 |
| Gross Margin | -71.44% |
| Net Profit Margin | -94.31% |
| Debt/Equity Ratio | 0% |
How did MRNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/06 22:27 |
| End of Day Share Price | 2025/11/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Moderna, Inc. is covered by 42 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Huidong Wang | Barclays |
| Harry Gillis | Berenberg |